Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 03, 2023 07:00 ET | Source: Genenta Science

Genenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indications

MILAN, Italy and NEW YORK, April 03, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of...
March 02, 2023 06:45 ET | Source: Genenta Science

FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme

MILAN and NEW YORK, March 02, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic...
February 07, 2023 07:00 ET | Source: Genenta Science

Genenta Science and AGC Biologics Enter Development and Manufacturing Service Agreement

MILAN, N.Y., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company engaged in the development of hematopoietic stem progenitor cell immuno-gene...
November 07, 2022 08:05 ET | Source: Genenta Science

Genenta Update at SITC22 Indicates Potential for Anti-Tumor Immune System Reset after Temferon™ Treatment in Glioblastoma Patients

• Signs of intra-tumor pro-inflammatory state in patients• Temferon™ induced immune system reset in preclinical studies• Macrophage and T cell profiles in patients’ tumor microenvironment echo...
October 24, 2022 07:30 ET | Source: Genenta Science

Genenta Provides First Half 2022 Business Update and Financial Results

Current dose escalation study data shows a median overall survival of 17 monthsAdding cohort to Phase 1/2a trial in GBM to assess additional conditioning regimenCash and cash equivalents of €34.7...
October 05, 2022 08:05 ET | Source: Genenta Science

Genenta to Present at Upcoming Scientific and Investor Conferences

MILAN, Italy and NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical stage immune-oncology company developing a cell-based platform harnessing the power of...
September 07, 2022 07:00 ET | Source: Genenta Science

Genenta to Present at Upcoming Investor Conferences

MILAN, Italy and NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical stage immune-oncology company developing a cell-based platform harnessing the power of...
July 25, 2022 06:00 ET | Source: Genenta Science

AmCham Italy and Genenta Science Announce the Bowling Green Bull Initiative

MILAN, Italy, July 25, 2022 (GLOBE NEWSWIRE) -- Bowling Green Bull (BGB) is an initiative to connect Italian companies, entrepreneurs and top managers aiming for international growth and expansion...
May 13, 2022 07:30 ET | Source: Genenta Science

Genenta to Present at Upcoming Scientific Congresses ASGCT, BTM, ASCO and EHA

MILAN, Italy and NEW YORK, May 13, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell...
May 09, 2022 07:30 ET | Source: Genenta Science

Genenta Appoints Industry Veteran Tim Obara as Head of Business Development

MILAN, Italy and NEW YORK, May 09, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell...